FutureTech II Acquisition Corp.
What Do They Do?
Seeks to combine with businesses through mergers or acquisitions, focusing on U.S. technology companies in biomedical life sciences, artificial intelligence and robotics.
10-K for FY2024, filed Apr 9, 2025We are a blank check company incorporated in Delaware on August 19, 2021. The Company was formed for the purpose of effecting a merger…View ↗
Although there is no restriction or limitation on what industry or geographic region our target operates in, it is our intention to pursue…View ↗
We will continue to focus on hardware technology companies that have large market potentials, mainly in areas of biomedical life science…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2024, filed Apr 9, 2025
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2025, filed Aug 23, 2025
−$80.6KView ↗
- ▲ +81% (Loss)
- vs −$44.5K in Q2 FY2024
-
Jul 8, 2026
Company says previously issued financial statements require restatement
The board said several previously issued annual and interim reports contain errors and must be corrected.
Sources
8-K, filed Jul 8, 2026
The Board of Directors (the “Board”) of FutureTech II Acquisition Corp. (the “Company”), after discussion with the Company’s management…View ↗
-
Feb 19, 2026
Company appoints CBIZ as its independent auditor
Sources
8-K, filed Feb 19, 2026
On February 17, 2026, the Chief Executive Officer and the Chairman of the Audit Committee of the Board of Directors of FutureTech II…View ↗
-
Jan 16, 2026
Adeptus resigns as the company’s independent auditor
Sources
8-K, filed Jan 16, 2026
On January 12, 2026, the Audit Committee of the Board of Directors (the “Audit Committee”) of FutureTech II Acquisition, Corp. (the…View ↗
-
Aug 18, 2025
Amended merger plan includes acquisitions of Cerevast Medical and Aegeria
Under the agreement, Longevity would acquire both companies before the mergers.
Sources
8-K, filed Aug 18, 2025
As previously disclosed, on August 12, 2025, FutureTech II Acquisition Corp., a Delaware corporation (the “Company”), entered into an…View ↗
A named merger target
The older report said no specific business combination target had been selected; the latest report describes a merger agreement with Longevity, a biopharmaceutical company focused on therapeutics, monitoring and digital health for diseases associated with aging.
10-K for FY2021, filed Mar 31, 2022 10-K for FY2024, filed Apr 9, 2025We have not selected any specific business combination target and we have not, nor has anyone on our behalf, initiated any substantive…View ↗
Broader target focus
The latest report adds biomedical life sciences to its hardware technology targets, alongside artificial intelligence and robotics; the older report emphasized hardware targets in artificial intelligence and robotics.
10-K for FY2021, filed Mar 31, 2022 10-K for FY2024, filed Apr 9, 2025We will focus on hardware technology companies that have large market potentials, mainly in areas of AI and Robotics.View ↗
We will continue to focus on hardware technology companies that have large market potentials, mainly in areas of biomedical life science…View ↗
Loading...
